Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00997503 · ClinicalTrials.gov registry record
TAXUS Libertē Post Approval Study
A clinical trial, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 4,199
- Enrollment target
NCT00997503 is a clinical trial that has completed, run by Boston Scientific Corporation. The registered enrollment target is 4,199 participants.
The verdict
NCT00997503 has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 4,199 participants
- Enrollment target
Study Summary
The TAXUS Libertē Post-Approval Study is an FDA-mandated prospective, multi-center study designed to collect real-world safety and clinical outcomes in approximately 4,200 patients receiving one or more TAXUS Liberté Paclitaxel-Eluting Stents and prasugrel as part of a dual antiplatelet therapy (DAPT) drug regimen. This study will also contribute patient data to an FDA-requested and industry-sponsored research study that will evaluate the optimal duration of dual antiplatelet therapy (DAPT Study).
Interventions
- DRUG placebo
- DRUG aspirin
- DRUG prasugrel
- DEVICE TAXUS Liberté Paclitaxel-Eluting Coronary Stent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,199 participants |
| Start Date | 2009-12 |
| Est. Completion | 2015-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00997503
The ClinicalTrials.gov registry entry for NCT00997503 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4,199 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which placebo is the first listed.
NCT00997503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00997503 about?
NCT00997503 is a clinical study titled "TAXUS Libertē Post Approval Study". The TAXUS Libertē Post-Approval Study is an FDA-mandated prospective, multi-center study designed to collect real-world safety and clinical outcomes in approximately 4,200 patients receiving one or more TAXUS Liberté Paclitaxel-Eluting Stents and prasugrel as part of a dual antiplatelet therapy (DAP...
What is the current status of trial NCT00997503?
This trial is currently completed. The enrollment target is 4,199 participants. The study started on 2009-12. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00997503?
The interventions under investigation include: placebo (DRUG), aspirin (DRUG), prasugrel (DRUG), TAXUS Liberté Paclitaxel-Eluting Coronary Stent (DEVICE).
Who is sponsoring clinical trial NCT00997503?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.